Investment Thesis
Co-Diagnostics exhibits severe operational distress with collapsing profitability despite healthy gross margins, indicating fundamental business model failure. The company is burning substantial cash with negative operating cash flow of -$22.9M against minimal revenue of $358.6K, making the current trajectory unsustainable even with adequate liquidity reserves.
Strengths
- Strong liquidity position with $11.4M cash and 3.81x current ratio
- Healthy gross margin of 77.7% indicates viable product economics at unit level
- Conservative capital structure with low debt-to-equity ratio of 0.05x
Risks
- Catastrophic operating losses of -$23.6M on near-zero revenue indicates severe commercialization failure
- Negative operating cash flow of -$22.9M annually will deplete cash reserves in approximately 5 quarters at current burn rate
- Revenue essentially flat YoY with no growth trajectory visible; business appears stalled or in decline
- Operating margin of -6588% and net margin of -5898% are unsustainable and indicate the company cannot convert sales into profits
- Negative ROE of -53.1% and ROA of -47.3% demonstrate severe capital inefficiency
Key Metrics to Watch
- Quarterly revenue trend - any stabilization or decline acceleration
- Operating cash burn rate - critical to cash runway estimation
- Operating expense reduction progress - evidence of cost control efforts
- Path to profitability or strategic pivots - restructuring or business model changes
Financial Metrics
Revenue
358.6K
Net Income
-21.2M
EPS (Diluted)
$-0.62
Free Cash Flow
-23.5M
Total Assets
44.7M
Cash
11.4M
Profitability Ratios
Gross Margin
77.7%
Operating Margin
-6,588.3%
Net Margin
-5,898.5%
ROE
-53.1%
ROA
-47.3%
FCF Margin
-6,555.5%
Balance Sheet & Liquidity
Current Ratio
3.81x
Quick Ratio
3.51x
Debt/Equity
0.05x
Debt/Assets
11.0%
Interest Coverage
-221.95x
Long-term Debt
1.9M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-22T18:40:11.069329 |
Data as of: 2025-09-30 |
Powered by Claude AI